Ławicki Sławomir, Bedkowska Grazyna Ewa, Gacuta-Szumarska Ewa, Czygier Małgorzata, Szmitkowski Maciej
Uniwersytet Medyczny w Białymstoku, Zakład Diagnostyki Biochemicznej.
Pol Merkur Lekarski. 2010 May;28(167):354-8.
Hematopoietic growth factors (HGFs) are involved in the regulation of growth hematopoietic cells. Some clinical investigations have shown an autologous production of HGFs in various human cell lines in vitro and by tumour cells in vivo, for example in endometrial cancer.
To evaluate the plasma levels and diagnostics utility of selected HGFs, such as SCF M-CSF, G-CSF in endometrial cancer patients and with myoma uteri.
We have investigated the plasma levels of HGFs and tumor marker like CA 125 in patients with endometrial cancer (55 women), with myoma uteri (30 patients) and in 30 healthy subjects. HGFs were determined using enzyme-linked immunosorbent assay (ELISA), CA 125 was measured by chemiluminescence immunoassay (CMIA).
SCF and M-CSF similarly to CA 125 plasma levels were significantly higher in endometrial cancer patients comparing to the healthy subjects. Furthermore M-CSF was significantly higher in endometrial cancer comparing to the myoma patients. The diagnostic sensitivity of M-CSF was high and slightly lower than CA 125 (51% and 60% respectively). The combined use of all tested cytokines resulted in the increased sensitivity range, especially with marker CA 125 (84%). Diagnostic specificities were high and equal for all tested cytokines and for CA 125(93%). Positive predictive values (PPV) were high for all tested parameters, and negative predictive values (NPV) were higher enough to exclude endometrial cancer.
Our study suggest that tested cytokines (HGFs) can be clinically useful in diagnostic of endometrial cancer patients. M-CSF can be clinically useful in differentiation of endometrial cancer and myoma uteri. Furthermore SCF and M-CSF showed usefulness in primary diagnostic of cancer uteri, especially with CA 125.
造血生长因子（HGFs）参与造血细胞生长的调节。一些临床研究表明，HGFs可在体外多种人类细胞系以及体内肿瘤细胞（如子宫内膜癌）中自体产生。
评估选定的造血生长因子（如干细胞因子（SCF）、巨噬细胞集落刺激因子（M-CSF）、粒细胞集落刺激因子（G-CSF））在子宫内膜癌患者和子宫肌瘤患者中的血浆水平及诊断效用。
我们研究了子宫内膜癌患者（55名女性）、子宫肌瘤患者（30名患者）以及30名健康受试者的造血生长因子血浆水平和肿瘤标志物（如CA 125）。使用酶联免疫吸附测定（ELISA）法测定造血生长因子，通过化学发光免疫测定（CMIA）法测量CA 125。
与健康受试者相比，子宫内膜癌患者的干细胞因子和巨噬细胞集落刺激因子血浆水平与CA 125相似，均显著升高。此外，与子宫肌瘤患者相比，子宫内膜癌患者的巨噬细胞集落刺激因子水平显著更高。巨噬细胞集落刺激因子的诊断敏感性较高，略低于CA 125（分别为51%和60%）。所有检测细胞因子联合使用可提高敏感性范围，尤其是与CA 125联合时（84%）。所有检测细胞因子和CA 125的诊断特异性均较高且相等（93%）。所有检测参数的阳性预测值（PPV）较高，阴性预测值（NPV）足以排除子宫内膜癌。
我们的研究表明，所检测的细胞因子（造血生长因子）在子宫内膜癌患者的诊断中可能具有临床应用价值。巨噬细胞集落刺激因子在子宫内膜癌和子宫肌瘤的鉴别诊断中可能具有临床应用价值。此外，干细胞因子和巨噬细胞集落刺激因子在子宫癌的初步诊断中显示出效用，尤其是与CA 125联合使用时。
